<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="79042">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02033746</url>
  </required_header>
  <id_info>
    <org_study_id>2013P001595</org_study_id>
    <nct_id>NCT02033746</nct_id>
  </id_info>
  <brief_title>Opiate Craving Reduction Study Using Post-detox Patients on Suboxone and Use of TEAS as Adjunctive Treatment</brief_title>
  <official_title>A Crossover Study Using Transdermal Electroacupuncture as Adjunctive Treatment to Reduce Opiate Cravings in Post-Detox Outpatients Receiving Buprenorphine-Naloxone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mclean Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mclean Hospital</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pilot study of 12 outpatients in early recovery from illicit drug use,post-detox and  on
      buprenorphine-naloxone maintenance will be offered 12 TEAS adjunct treatments over 6
      weeks(X2/week) to ascertain if they experience  any improvement in mood,sleep,overall
      quality of life and decrease drug cravings ultimately while facing everyday life stressors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  this crossover study will involve participants who will be randomized into two
           treatment groups,A&amp;B. TEAS treatments will be given for 30 minutes,X2/week,for 6
           weeks(12total sessions). Group A will receive 2 weeks(4 sessions) of active treatment
           followed by 4 weeks of sham treatment(8 sessions). Group B will receive 2 weeks(4
           sessions) of sham treatment,2 weeks (4 sessions)of real treatment,and finally 2 weeks
           (4 sessions) of sham treatment.

        -  parameters to be measured include vital signs and questionnaires weeks 1,3,5,6 to
           assess self-reported past 14-day substance use,alcohol and drug craving,withdrawal
           symptoms,sleep,mood,pain and overall quality of life.

        -  goals include better lives for post-detox opiate addicts as they incorporate this
           treatment into their lives,saving themselves and loved ones more horror,and their
           communities resources.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">March 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of participants who attend all 12 Transdermal Electroacupuncture (TEAS) sessions</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants who experience improvement in mood</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mood measured by self-report on the Quick Inventory of Depressive Symptomatology (QIDS-SR-16) questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who experience improvement in sleep</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Sleep patterns measure by self report through the Pittsburgh Sleep Quality Index (PSQI) questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who experience improvement in Quality-of-Life</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Quality-of-Life measured by self-report through Short Form (SF)-36 questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who report fewer cravings for drugs and alcohol</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cravings for drugs and alcohol measure by self-report through the Brief Addiction Monitor (BAM), the Craving Scale (CS), the Subjective Opiate Withdrawal Scale (SOWS), Substance Use Report, and a Brief Pain Inventory</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Opioid-use Disorder</condition>
  <arm_group>
    <arm_group_label>Transdermal Electroacupuncture - Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>week 1-2 real treatment, week 3-6 sham treatment  with Han's Acupoint Nerve Stimulator while receiving concurrent buprenorphine-naloxone as prescribed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Transdermal Electroacupuncture - Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>week 1-2 real treatment, week 3-6 sham treatment  with Han's Acupoint Nerve Stimulator  treatment while receiving concurrent buprenorphine-naloxone as prescribed</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Han's Acupoint Nerve Stimulator</intervention_name>
    <description>frequency delivery(3 seconds of 2 Hz followed by 3 seconds of 100 Hz(dense disperse method).</description>
    <arm_group_label>Transdermal Electroacupuncture - Arm A</arm_group_label>
    <arm_group_label>Transdermal Electroacupuncture - Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-59 years old

          -  early recovery(0-3months of abstinence

          -  not currently detoxing

          -  maintained on buprenorphine-naloxone under the care of qualified MD

          -  proficient in the English language

          -  abstinent from other illicit drug use disorders or co-occuring alcohol dependence

        Exclusion Criteria:

          -  history of prior acupuncture treatment

          -  having acute,psychiatric symptoms which would pose safety concerns,or an adherence to
             treatment barrier(active suicidality/psychosis/mania)

          -  cognitive disorders*not competent to give informed consent

          -  active cardiac disease or EKG abnormalities or with cardiac pacemaker

          -  currently detoxing from alcohol or illicit drugs

          -  inability or  non-intention to attend all treatment sessions*history of
             seizures*pregnancy or breast feeding.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barbara A MacIntyre, MSN,RN</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mclean Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Barbara A MacIntyre, MSN, RN</last_name>
    <phone>617-855-2771</phone>
    <email>bmacintyre@partners.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>McLean Hospital</name>
      <address>
        <city>Belmont</city>
        <state>Massachusetts</state>
        <zip>02478</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Barbara A MacIntyre, MSN, RN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 9, 2014</lastchanged_date>
  <firstreceived_date>January 3, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mclean Hospital</investigator_affiliation>
    <investigator_full_name>Barbara MacIntyre MSN,RN</investigator_full_name>
    <investigator_title>Barbara MacIntyre MSN,RN</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Buprenorphine</mesh_term>
    <mesh_term>Naloxone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
